← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Cogentis Therapeutics, Inc.
Baltimore, MD
$2,944,124
Total funding
2
Grants
Funding over time
peak $1.2M · FY2018–22$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$2,944,124 · 2
By mechanism
R44$2,210,678 · 1
R43$733,446 · 1
Investigators at Cogentis Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Development of a Synthetic, Cell-Permeable Peptide for the Inhibition of CDK5-p25 Hyperactivity in Amyotrophic Lateral Sclerosis$1,183,364
R44 · FY2021 · NS
Development of a Synthetic, Cell-Permeable Peptide for the Inhibition of CDK5-p25 Hyperactivity in Amyotrophic Lateral Sclerosis$1,027,314
R44 · FY2022 · NS
Development of CDK5-p25 modulator to treat Alzheimer's Disease and Frontotemporal Dementia$497,121
R43 · FY2018 · AG
Development of CDK5-p25 modulator to treat Alzheimer's Disease and Frontotemporal Dementia$236,325
R43 · FY2020 · AG